1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Top 50 Big Pharma Partnering and M&A Deal Trends 2010-2015 - CP1010 - Apr2015

The Top 50 Big Pharma Partnering and M&A Deal Trends report provides comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

The Top 50 Big Pharma Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

Top 50 Big Pharma Partnering and M&A Deal Trends provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2010 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

This premier report provides all the information you require to better understand big pharma partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big pharma companies dealmaking trends over the last four years.

This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of big pharma’s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big pharma companies based on 2013 pharmaceutical revenues and dealmaking activity since 2010.

Chapter 3 reviews the top partnering and M&A deals of 2010-2015 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big pharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big pharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big pharma company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners’ negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 3,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big pharma partners effectively and efficiently.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners’ negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 3,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big pharma partners effectively and efficiently.

Top 50 Big Pharma Partnering and M&A Deal Trends provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company’s dealmaking activity since 2010, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2010 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Top 50 Big Pharma Partnering and MandA Deal Trends 2010-2015 - CP1010 - Apr2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Big pharma top 50 dealmaking activity

2.1. Introduction
2.2. Big pharma partnering over the years
2.4. Big pharma partnering by deal type
2.5. Big pharma partnering industry sector
2.6. Big pharma partnering by stage of development
2.7. Big pharma partnering by technology type
2.8. Big pharma partnering by therapy area
2.9. Big pharma MandA over the years

Chapter 3 - Top big pharma deals by value

3.1. Introduction
3.2. Big pharma partnering
3.3. Big pharma MandA

Chapter 4 - Submitting Opportunities to Big pharma

4.1. How to submit an opportunity
4.2. Opportunity submission template
4.3. Sending emails
4.4. Face to face at partnering events
4.5. Online submission forms

Chapter 5 - Forthcoming big pharma partnering events

5.1. Forthcoming events

Chapter 6 - Big pharma Company Profiles

6.1. Introduction
6.2. Field definitions
6.3. Big pharma company profiles in alphabetical order
Abbott
Abbvie
Actavis
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo
Forest Laboratories
Fresenius
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson and Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue Pharma
Roche
Sanofi
Servier
Shionogi
Shire
Sun Pharmaceutical
Takeda
Teva
UCB
Valeant

Chapter 7 - Resources

Appendices
Appendix 1 - Deal type definitions
Appendix 2 - Example contract document
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Upgrades to subscription access products

TABLE OF FIGURES

Figure 1: Big pharma partnering 2010-2015
Figure 2: Big pharma - top 50 partnering activity 2010-2015
Figure 3: Big pharma deal frequency - 2010-2015
Figure 4: Big pharma partnering by deal type 2010-2015
Figure 5: Big pharma partnering by industry sector 2010-2015
Figure 6: Big pharma partnering by stage of development 2010-2015
Figure 7: Big pharma partnering by technology type 2010-2015
Figure 8: Big pharma partnering by therapy area 2010-2015
Figure 9: Big pharma MandA 2010-2015
Figure 10: Big pharma - top 50 MandA activity 2010-2015
Figure 11: Big pharma MandA deal frequency 2010-2015
Figure 12: Leading partnering deals by value, 2010-2015
Figure 13: Leading MandA deals involving big pharma by value, 2010-2015
Figure 14: Typical partnering opportunity submission template
Figure 15: Company profile template and definitions used in report
Figure 16: Abbott dealmaking frequency 2010-2015
Figure 17: Abbott deals by type
Figure 18: Abbott deals by industry sector
Figure 19: Abbott deals by technology type
Figure 20: Abbott deals by stage of development
Figure 21: Abbott deals by therapy area
Figure 22: Abbvie dealmaking frequency 2010-2015
Figure 23: Abbvie deals by type
Figure 24: Abbvie deals by industry sector
Figure 25: Abbvie deals by technology type
Figure 26: Abbvie deals by stage of development
Figure 27: Abbvie deals by therapy area
Figure 28: Actavis dealmaking frequency 2010-2015
Figure 29: Actavis deals by type
Figure 30: Actavis deals by industry sector
Figure 31: Actavis deals by technology type
Figure 32: Actavis deals by stage of development
Figure 33: Partnering deals by therapy area
Figure 34: Allergan dealmaking frequency 2010-2015
Figure 35: Allergan deals by type
Figure 36: Allergan deals by industry sector
Figure 37: Allergan deals by technology type
Figure 38: Allergan deals by stage of development
Figure 39: Allergan deals by therapy area
Figure 40: Amgen dealmaking frequency 2010-2015
Figure 41: Amgen deals by type
Figure 42: Amgen deals by industry sector
Figure 43: Amgen deals by technology type
Figure 44: Amgen deals by stage of development
Figure 45: Amgen deals by therapy area
Figure 46: Aspen Pharmacare dealmaking frequency 2010-2015
Figure 47: Aspen Pharmacare deals by type
Figure 48: Aspen Pharmacare deals by industry sector
Figure 49: Aspen Pharmacare deals by technology type
Figure 50: Aspen Pharmacare deals by stage of development
Figure 51: Aspen Pharmacare deals by therapy area
Figure 52: Astellas dealmaking frequency 2010-2015
Figure 53: Astellas deals by type
Figure 54: Astellas deals by industry sector
Figure 55: Astellas deals by technology type
Figure 56: Astellas deals by stage of development
Figure 57: Astellas deals by therapy area
Figure 58: AstraZeneca dealmaking frequency 2010-2015
Figure 59: AstraZeneca deals by type
Figure 60: AstraZeneca deals by industry sector
Figure 61: AstraZeneca deals by technology type
Figure 62: AstraZeneca deals by stage of development
Figure 63: AstraZeneca deals by therapy area
Figure 64: Baxter dealmaking frequency 2010-2015
Figure 65: Baxter deals by type
Figure 66: Baxter deals by industry sector
Figure 67: Baxter deals by technology type
Figure 68: Baxter deals by stage of development
Figure 69: Baxter deals by therapy area
Figure 70: Bayer dealmaking frequency 2010-2015
Figure 71: Bayer deals by type
Figure 72: Bayer deals by industry sector
Figure 73: Bayer deals by technology type
Figure 74: Bayer deals by stage of development
Figure 75: Bayer deals by therapy area
Figure 76: Biogen Idec dealmaking frequency 2010-2015
Figure 77: Biogen Idec deals by type
Figure 78: Biogen Idec deals by industry sector
Figure 79: Biogen Idec deals by technology type
Figure 80: Biogen Idec deals by stage of development
Figure 81: Partnering deals by therapy area
Figure 82: Boehringer Ingelheim dealmaking frequency 2010-2015
Figure 83: Boehringer Ingelheim deals by type
Figure 84: Boehringer Ingelheim deals by industry sector
Figure 85: Boehringer Ingelheim deals by technology type
Figure 86: Boehringer Ingelheim deals by stage of development
Figure 87: Partnering deals by therapy area
Figure 88: Bristol-Myers Squibb dealmaking frequency 2010-2015
Figure 89: Bristol-Myers Squibb deals by type
Figure 90: Bristol-Myers Squibb deals by industry sector
Figure 91: Bristol-Myers Squibb deals by technology type
Figure 92: Bristol-Myers Squibb deals by stage of development
Figure 93: Partnering deals by therapy area
Figure 94: Celgene dealmaking frequency 2010-2015
Figure 95: Celgene deals by type
Figure 96: Celgene deals by industry sector
Figure 97: Celgene deals by technology type
Figure 98: Celgene deals by stage of development
Figure 99: Partnering deals by therapy area
Figure 100: Chugai dealmaking frequency 2010-2015
Figure 101: Chugai deals by type
Figure 102: Chugai deals by industry sector
Figure 103: Chugai deals by technology type
Figure 104: Chugai deals by stage of development
Figure 105: Chugai deals by therapy area
Figure 106: CSL dealmaking frequency 2010-2015
Figure 107: CSL deals by type
Figure 108: CSL deals by industry sector
Figure 109: CSL deals by technology type
Figure 110: CSL deals by stage of development
Figure 111: CSL deals by therapy area
Figure 112: Daiichi Sankyo dealmaking frequency 2010-2015
Figure 113: Daiichi Sankyo deals by type
Figure 114: Daiichi Sankyo deals by industry sector
Figure 115: Daiichi Sankyo deals by technology type
Figure 116: Daiichi Sankyo deals by stage of development
Figure 117: Daiichi Sankyo deals by therapy area
Figure 118: Dainippon Sumitomo dealmaking frequency 2010-2015
Figure 119: Dainippon Sumitomo deals by type
Figure 120: Dainippon Sumitomo deals by industry sector
Figure 121: Dainippon Sumitomo deals by technology type
Figure 122: Dainippon Sumitomo deals by stage of development
Figure 123: Dainippon Sumitomo deals by therapy area
Figure 124: Eisai dealmaking frequency 2010-2015
Figure 125: Eisai deals by type
Figure 126: Eisai deals by industry sector
Figure 127: Eisai deals by technology type
Figure 128: Eisai deals by stage of development
Figure 129: Eisai deals by therapy area
Figure 130: Eli Lilly dealmaking frequency 2010-2015
Figure 131: Eli Lilly deals by type
Figure 132: Eli Lilly deals by industry sector
Figure 133: Eli Lilly deals by technology type
Figure 134: Eli Lilly deals by stage of development
Figure 135: Partnering deals by therapy area
Figure 136: Endo dealmaking frequency 2010-2015
Figure 137: Endo deals by type
Figure 138: Endo deals by industry sector
Figure 139: Endo deals by technology type
Figure 140: Endo deals by stage of development
Figure 141: Endo deals by therapy area
Figure 142: Forest Laboratories dealmaking frequency 2010-2015
Figure 143: Forest Laboratories deals by type
Figure 144: Forest Laboratories deals by industry sector
Figure 145: Forest Laboratories deals by technology type
Figure 146: Forest Laboratories deals by stage of development
Figure 147: Forest Laboratories deals by therapy area
Figure 148: Fresenius dealmaking frequency 2010-2015
Figure 149: Fresenius deals by type
Figure 150: Fresenius deals by industry sector
Figure 151: Fresenius deals by technology type
Figure 152: Fresenius deals by stage of development
Figure 153: Fresenius deals by therapy area
Figure 154: Gilead Sciences dealmaking frequency 2010-2015
Figure 155: Gilead Sciences deals by type
Figure 156: Gilead Sciences deals by industry sector
Figure 157: Gilead Sciences deals by technology type
Figure 158: Gilead Sciences deals by stage of development
Figure 159: Gilead Sciences deals by therapy area
Figure 160: GlaxoSmithKline dealmaking frequency 2010-2015
Figure 161: GlaxoSmithKline deals by type
Figure 162: GlaxoSmithKline deals by industry sector
Figure 163: GlaxoSmithKline deals by technology type
Figure 164: GlaxoSmithKline deals by stage of development
Figure 165: GlaxoSmithKline deals by therapy area
Figure 166: Grifols dealmaking frequency 2010-2015
Figure 167: Grifols deals by type
Figure 168: Grifols deals by industry sector
Figure 169: Grifols deals by technology type
Figure 170: Grifols deals by stage of development
Figure 171: Partnering deals by therapy area
Figure 172: Hospira dealmaking frequency 2010-2015
Figure 173: Hospira deals by type
Figure 174: Hospira deals by industry sector
Figure 175: Hospira deals by technology type
Figure 176: Hospira deals by stage of development
Figure 177: Hospira deals by therapy area
Figure 178: Johnson and Johnson dealmaking frequency 2010-2015
Figure 179: Johnson and Johnson deals by type
Figure 180: Johnson and Johnson deals by industry sector
Figure 181: Johnson and Johnson deals by technology type
Figure 182: Johnson and Johnson deals by stage of development
Figure 183: Johnson and Johnson deals by therapy area
Figure 184: Kyowa Hakko Kirin dealmaking frequency 2010-2015
Figure 185: Kyowa Hakko Kirin deals by type
Figure 186: Kyowa Hakko Kirin deals by industry sector
Figure 187: Kyowa Hakko Kirin deals by technology type
Figure 188: Kyowa Hakko Kirin deals by stage of development
Figure 189: Kyowa Hakko Kirin deals by therapy area
Figure 190: Lundbeck dealmaking frequency 2010-2015
Figure 191: Lundbeck deals by type
Figure 192: Lundbeck deals by industry sector
Figure 193: Lundbeck deals by technology type
Figure 194: Lundbeck deals by stage of development
Figure 195: Lundbeck deals by therapy area
Figure 196: Menarini dealmaking frequency 2010-2015
Figure 197: Menarini deals by type
Figure 198: Menarini deals by industry sector
Figure 199: Menarini deals by technology type
Figure 200: Menarini deals by stage of development
Figure 201: Menarini deals by therapy area
Figure 202: Merck and Co. dealmaking frequency 2010-2015
Figure 203: Merck and Co.deals by type
Figure 204: Merck and Co.deals by industry sector
Figure 205: Merck and Co.deals by technology type
Figure 206: Merck and Co.deals by stage of development
Figure 207: Merck and Co.deals by therapy area
Figure 208: Merck KGaA dealmaking frequency 2010-2015
Figure 209: Merck KGaA deals by type
Figure 210: Merck KGaA deals by industry sector
Figure 211: Merck KGaA deals by technology type
Figure 212: Merck KGaA deals by stage of development
Figure 213: Merck KGaA deals by therapy area
Figure 214: Mitsubishi Tanabe dealmaking frequency 2010-2015
Figure 215: Mitsubishi Tanabe deals by type
Figure 216: Mitsubishi Tanabe deals by industry sector
Figure 217: Mitsubishi Tanabe deals by technology type
Figure 218: Mitsubishi Tanabe deals by stage of development
Figure 219: Mitsubishi Tanabe deals by therapy area
Figure 220: Mylan dealmaking frequency 2010-2015
Figure 221: Mylan deals by type
Figure 222: Mylan deals by industry sector
Figure 223: Mylan deals by technology type
Figure 224: Mylan deals by stage of development
Figure 225: Mylan deals by therapy area
Figure 226: Novartis dealmaking frequency 2010-2015
Figure 227: Novartis deals by type
Figure 228: Novartis deals by industry sector
Figure 229: Novartis deals by technology type
Figure 230: Novartis deals by stage of development
Figure 231: Partnering deals by therapy area
Figure 232: Novo Nordisk dealmaking frequency 2010-2015
Figure 233: Novo Nordisk deals by type
Figure 234: Novo Nordisk deals by industry sector
Figure 235: Novo Nordisk deals by technology type
Figure 236: Novo Nordisk deals by stage of development
Figure 237: Novo Nordisk deals by therapy area
Figure 238: Otsuka dealmaking frequency 2010-2015
Figure 239: Otsuka deals by type
Figure 240: Otsuka deals by industry sector
Figure 241: Otsuka deals by technology type
Figure 242: Otsuka deals by stage of development
Figure 243: Otsuka deals by therapy area
Figure 244: Pfizer dealmaking frequency 2010-2015
Figure 245: Pfizer deals by type
Figure 246: Pfizer deals by industry sector
Figure 247: Pfizer deals by technology type
Figure 248: Pfizer deals by stage of development
Figure 249: Pfizer deals by therapy area
Figure 250: Purdue dealmaking frequency 2010-2015
Figure 251: Purdue deals by type
Figure 252: Purdue deals by industry sector
Figure 253: Purdue deals by technology type
Figure 254: Purdue deals by stage of development
Figure 255: Purdue deals by therapy area
Figure 256: Roche dealmaking frequency 2010-2015
Figure 257: Roche deals by type
Figure 258: Roche deals by industry sector
Figure 259: Roche deals by technology type
Figure 260: Roche deals by stage of development
Figure 261: Roche deals by therapy area
Figure 262: Sanofi frequency 2010-2015
Figure 263: Sanofi deals by type
Figure 264: Sanofi deals by industry sector
Figure 265: Sanofi deals by technology type
Figure 266: Sanofi deals by stage of development
Figure 267: Sanofi deals by therapy area
Figure 268: Servier dealmaking frequency 2010-2015
Figure 269: Servier deals by type
Figure 270: Servier deals by industry sector
Figure 271: Servier deals by technology type
Figure 272: Servier deals by stage of development
Figure 273: Servier deals by therapy area
Figure 274: Shionogi dealmaking frequency 2010-2015
Figure 275: Shionogi deals by type
Figure 276: Shionogi deals by industry sector
Figure 277: Shionogi deals by technology type
Figure 278: Shionogi deals by stage of development
Figure 279: Shionogi deals by therapy area
Figure 280: Shire dealmaking frequency 2010-2015
Figure 281: Shire deals by type
Figure 282: Shire deals by industry sector
Figure 283: Shire deals by technology type
Figure 284: Shire deals by stage of development
Figure 285: Shire deals by therapy area
Figure 286: Sun Pharmaceutical dealmaking frequency 2010-2015
Figure 287: Sun Pharmaceutical deals by type
Figure 288: Sun Pharmaceutical deals by industry sector
Figure 289: Sun Pharmaceutical deals by technology type
Figure 290: Sun Pharmaceutical deals by stage of development
Figure 291: Sun Pharmaceutical deals by therapy area
Figure 292: Takeda dealmaking frequency 2010-2015
Figure 293: Takeda deals by type
Figure 294: Takeda deals by industry sector
Figure 295: Takeda deals by technology type
Figure 296: Takeda deals by stage of development
Figure 297: Takeda deals by therapy area
Figure 298: Teva dealmaking frequency 2010-2015
Figure 299: Teva deals by type
Figure 300: Teva deals by industry sector
Figure 301: Teva deals by technology type
Figure 302: Teva deals by stage of development
Figure 303: Teva deals by therapy area
Figure 304: UCB dealmaking frequency 2010-2015
Figure 305: UCB deals by type
Figure 306: UCB deals by industry sector
Figure 307: UCB deals by technology type
Figure 308: UCB deals by stage of development
Figure 309: UCB deals by therapy area
Figure 310: Valeant: Dealmaking frequency 2010-2015
Figure 311: Valeant: Partnering deals by type
Figure 312: Valeant: Partnering deals by industry sector
Figure 313: Valeant: Partnering deals by technology type
Figure 314: Valeant: Partnering deals by stage of development
Figure 315: Valeant: Partnering deals by therapy area
Figure 316: Online partnering resources
Figure 317: Deal type definitions
Figure 318: Licensing and collaboration agreement between Bayer Healthcare and Regeneron Pharmaceuticals, January 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.